Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice.
作者信息
Al-Ibraheem Akram
机构信息
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan.
出版信息
World J Nucl Med. 2023 Sep 20;22(3):171-173. doi: 10.1055/s-0043-1774733. eCollection 2023 Sep.
Abstract
摘要
相似文献
1
Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice.发展中国家的诊疗一体化：应对从培训到实践的挑战与潜力
World J Nucl Med. 2023 Sep 20;22(3):171-173. doi: 10.1055/s-0043-1774733. eCollection 2023 Sep.
2
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.治疗诊断学实践的培训、认证和指南的重要性：澳大利亚的观点。
J Nucl Med. 2022 Jun;63(6):819-822. doi: 10.2967/jnumed.122.263996. Epub 2022 Apr 7.
3
Medical practice in the face of economic meltdown: peculiar challenges in Nigeria and other developing countries.经济崩溃背景下的医疗实践：尼日利亚及其他发展中国家面临的特殊挑战。
Niger J Med. 2009 Oct-Dec;18(4):360-4. doi: 10.4314/njm.v18i4.51225.
4
Organic agriculture and undernourishment in developing countries: main potentials and challenges.有机农业与发展中国家的营养不足问题：主要潜力与挑战。
Crit Rev Food Sci Nutr. 2013;53(9):917-28. doi: 10.1080/10408398.2011.573886.
5
Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine.新冠病毒抗病毒药物的诊疗一体化：全球精准/个性化医学的前景与挑战
OMICS. 2023 Jan;27(1):6-14. doi: 10.1089/omi.2022.0151. Epub 2023 Jan 4.
6
Radiation protection infrastructure-challenges in developing countries.辐射防护基础设施——发展中国家面临的挑战
J Radiol Prot. 2021 Aug 19;41(3). doi: 10.1088/1361-6498/ac0c00.
7
Advanced Physiotherapy Practice: A qualitative study on the potential challenges and barriers to implementation in Ghana.高级物理疗法实践：加纳实施的潜在挑战和障碍的定性研究。
Physiother Theory Pract. 2020 Feb;36(2):307-315. doi: 10.1080/09593985.2018.1484535. Epub 2018 Jun 13.
8
Screening for hyperglycemia in the developing world: rationale, challenges and opportunities.发展中国家的高血糖筛查：理由、挑战和机遇。
Diabetes Res Clin Pract. 2012 Nov;98(2):199-208. doi: 10.1016/j.diabres.2012.08.003. Epub 2012 Sep 10.
9
U.S. trainees' experiences of ethical challenges during research in low- and middle-income countries: A mixed methods study.美国受训者在中低收入国家进行研究时所面临的伦理挑战经历：一项混合方法研究。
Glob Public Health. 2022 Jul;17(7):1433-1449. doi: 10.1080/17441692.2021.1933124. Epub 2021 Jun 1.
10
Pharmacogenomics, Theranostics and Personalized Medicine - the complexities of clinical trials: challenges in the developing world.药物基因组学、治疗诊断学与个性化医疗——临床试验的复杂性：发展中世界面临的挑战。
Appl Transl Genom. 2013 May 14;2:17-21. doi: 10.1016/j.atg.2013.05.002. eCollection 2013 Dec 1.
引用本文的文献
1
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.靶向放射性配体疗法：神经内分泌肿瘤和转移性前列腺癌中镥/锕治疗期间的物理与生物学、内照射剂量学及其他实际问题
Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025.
2
Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.利用铽放射性同位素推动临床进展：一项系统综述。
Nucl Med Mol Imaging. 2025 Feb;59(1):50-61. doi: 10.1007/s13139-024-00891-0. Epub 2024 Nov 12.
3
Analysis of Molecular Imaging Biomarkers Derived from [F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [Ac]Ac-PSMA-617-Augmented [Lu]Lu-PSMA-617 Radioligand Therapy.去势抵抗性前列腺癌中源自[F]FDG PET/CT的分子影像生物标志物分析：全身总病变糖酵解（TLG）预测接受[Ac]Ac-PSMA-617增强的[Lu]Lu-PSMA-617放射性配体治疗患者的总生存期
Cancers (Basel). 2024 Oct 19;16(20):3532. doi: 10.3390/cancers16203532.
4
A New Era for PET/CT: Applications in Non-Tumorous Renal Pathologies.PET/CT的新时代：在非肿瘤性肾脏疾病中的应用
J Clin Med. 2024 Aug 7;13(16):4632. doi: 10.3390/jcm13164632.
5
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival.前列腺特异性膜抗原放射性配体治疗中分子影像与实验室基线生物标志物分析：全身总病变前列腺特异性膜抗原（TLP）预测总生存期
Cancers (Basel). 2024 Jul 26;16(15):2670. doi: 10.3390/cancers16152670.
6
Efficacy and safety of rechallenge [Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).在 mCRPC 患者初始部分缓解后重新使用 [Lu]Lu-PSMA-617 RLT 的疗效和安全性：前瞻性登记研究（REALITY 研究）的评估。
Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4151-4162. doi: 10.1007/s00259-024-06825-4. Epub 2024 Jul 15.
7
From Despair to Hope: First Arabic Experience of Lu-PSMA and Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.从绝望到希望：卢-PSMA和钍-PSMA治疗转移性去势抵抗性前列腺癌的首例阿拉伯语地区经验
Cancers (Basel). 2024 May 23;16(11):1974. doi: 10.3390/cancers16111974.
8
Intense prostate-specific membrane antigen receptor expression in coronary artery pypass graft scar tissue: A potential molecular imaging pitfall.冠状动脉搭桥移植瘢痕组织中前列腺特异性膜抗原受体的高表达：分子成像的一个潜在陷阱。
Acta Radiol Open. 2024 Mar 28;13(2):20584601241240318. doi: 10.1177/20584601241240318. eCollection 2024 Feb.
9
[Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lu]Lu-PSMA-617.镥[177Lu]比伐卢定联合替罗非班治疗急性 ST 段抬高型心肌梗死的疗效及安全性
Theranostics. 2024 Feb 24;14(5):1829-1840. doi: 10.7150/thno.92273. eCollection 2024.
10
Guiding principles on the education and practice of theranostics.治疗诊断学教育与实践指导原则
Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320-2331. doi: 10.1007/s00259-024-06657-2. Epub 2024 Mar 8.
本文引用的文献
1
Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer.Tb-PSMA 大放异彩：前列腺癌诊疗领域的一颗新星。
Nucl Med Mol Imaging. 2023 Aug;57(4):168-171. doi: 10.1007/s13139-023-00804-7. Epub 2023 Apr 26.
2
Tb-PSMA Radioligand Therapy: First-in-Humans SPECT/CT Imaging.钆-前列腺特异性膜抗原放射性配体疗法：首例人体单光子发射计算机断层扫描/计算机断层扫描成像
J Nucl Med. 2023 Aug;64(8):1322-1323. doi: 10.2967/jnumed.122.265291. Epub 2023 Feb 9.
3
Cancer diagnosis in areas of conflict.冲突地区的癌症诊断。
Front Oncol. 2022 Dec 22;12:1087476. doi: 10.3389/fonc.2022.1087476. eCollection 2022.
4
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.治疗诊断学实践的培训、认证和指南的重要性：澳大利亚的观点。
J Nucl Med. 2022 Jun;63(6):819-822. doi: 10.2967/jnumed.122.263996. Epub 2022 Apr 7.
5
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者（NETTER-1）：一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
6
Diagnostic Performance and Clinical Impact of Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).镓-PSMA-11 PET/CT 成像在根治性治疗后早期复发前列腺癌中的诊断性能和临床影响：一项前瞻性多中心研究（IAEA-PSMA 研究）。
J Nucl Med. 2022 Feb;63(2):240-247. doi: 10.2967/jnumed.120.261886. Epub 2021 Jul 2.
7
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
8
Status of Nuclear Medicine in Latin America and the Caribbean: IAEA Analysis of Development in the Past 6 Years.拉丁美洲和加勒比地区核医学现状：国际原子能机构对过去六年发展情况的分析
J Nucl Med. 2021 Jun 1;62(6):23N-29N.
9
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.核医学、分子影像与诊疗一体化的未来
J Nucl Med. 2020 Dec;61(Suppl 2):263S-272S. doi: 10.2967/jnumed.120.254532.
10
Theranostic approaches in nuclear medicine: current status and future prospects.核医学中的治疗诊断学方法：现状与未来展望。
Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19.
Zotero 插件